In June 2011 the British Hypertension Society, after appraising the quality of publications questioning the appropriateness of population salt reduction, issued a statement supporting the implementation of national and global programmes of moderate reduction in salt intake. The Society now publishes a new statement in light of more recent publications.
The Consensus Statement was published in Heart in November 2014. The above links to the online open-access article.
Medtronic announced on January 9th 2014 that a large randomised controlled trial of renal denervation in 530 people with resistant hypertension using the unipolar Symplicity Catheter has not met the primary endpoint for blood pressure reduction.
Commonly prescribed effervescent, dispersible and soluble medicines containing sodium – used by millions of patients every day – are placing them at a significantly increased risk of cardiovascular events, a new study from the University of Dundee and University College London has shown.
It is thought that between a third and a half of all medicines prescribed for long-term conditions are not taken as recommended. ‘Simplifying the dosing regimen’ is one way of improving patient adherence as suggested by the NICE medicines adherence guidelines.
Statement on RESPeRATE device April 2012
The BHS has received a number of queries regarding this device since it appeared on the NHS Drug Tariff. This statement puts forward the BHS view.
Renal Denervation – Joint UK Societies Summary on Renal Denervation
The Joint UK Societies Consensus on Renal Denervation for resistant hypertension
This Joint Societies’ Consensus Statement was prepared to support the National Institute of Health and Clinical Excellence Interventional Procedure Guidance on Renal Denervation (NICE IP923) by representatives of key stakeholder societies.
Cocrane Review on salt
The purpose of this statement is to put the findings of the Cochrane Review into the context of the broader CVD prevention agenda
Dietary Salt Reduction and the Risk of Cardiovascular Disease
BHS response to a 2011 publication in the Journal of the American Medical Association reporting that a low salt intake ‘increases’ the risk of CVD.
ARBs and the risk of cancer
BHS response to a 2010 publication in the journal Lancet Oncology which reported that ARBs may be associated with a modestly increased risk of incident cancer
Aspirin in primary prevention of CVD
BHS response to reports questioning the benefits of aspirin use in those with no history of prior cardiovascular disease, including those with diabetes particularly in the context of the known increase in risk of gastrointestinal bleeding
BHS strategic Review 2009
A strategic review of current activities and future aims and objectives to guide development of the BHS between 2010-2016.
The ‘ACCELERATE’ study of 1250 patients with hypertension, published in the Lancet (00.01 on 13th January 2011), shows that a new accelerated treatment programme lowers blood pressure faster, more effectively, and with fewer side effects than conventional treatment.